CATALYST PHARMA (CN2.SG)
CATALYST PHARMA (CN2.SG) operates in Diversified Metals & Mining.
CATALYST PHARMA (CN2.SG) (CN2) - Total Assets
Latest total assets as of September 2024: €772.01 Million EUR
Based on the latest financial reports, CATALYST PHARMA (CN2.SG) (CN2) holds total assets worth €772.01 Million EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CATALYST PHARMA (CN2.SG) - Total Assets Trend (2016–2023)
This chart illustrates how CATALYST PHARMA (CN2.SG)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CATALYST PHARMA (CN2.SG) - Asset Composition Analysis
Current Asset Composition (December 2023)
CATALYST PHARMA (CN2.SG)'s total assets of €772.01 Million consist of 46.7% current assets and 53.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.3% |
| Accounts Receivable | €53.51 Million | 11.4% |
| Inventory | €15.64 Million | 3.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €194.05 Million | 41.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how CATALYST PHARMA (CN2.SG)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CATALYST PHARMA (CN2.SG)'s current assets represent 46.7% of total assets in 2023, a decrease from 99.4% in 2016.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2023, down from 33.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 41.3% of total assets.
CATALYST PHARMA (CN2.SG) Competitors by Total Assets
Key competitors of CATALYST PHARMA (CN2.SG) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
CATALYST PHARMA (CN2.SG) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - CATALYST PHARMA (CN2.SG) generates 0.85x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, CATALYST PHARMA (CN2.SG) generates $ 15.19 in net profit.
CATALYST PHARMA (CN2.SG) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.11 | 3.32 | 4.62 |
| Quick Ratio | 4.92 | 3.17 | 4.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €433.60 Million | € 134.21 Million | € 87.26 Million |
CATALYST PHARMA (CN2.SG) - Advanced Valuation Insights
This section examines the relationship between CATALYST PHARMA (CN2.SG)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | €470.11 Million |
| Market Capitalization | $199.82K USD |
Valuation Analysis
Below Book Valuation: The market values CATALYST PHARMA (CN2.SG)'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CATALYST PHARMA (CN2.SG)'s assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CATALYST PHARMA (CN2.SG) (2016–2023)
The table below shows the annual total assets of CATALYST PHARMA (CN2.SG) from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €470.11 Million | +25.15% |
| 2022-12-31 | €375.63 Million | +57.97% |
| 2021-12-31 | €237.79 Million | +23.62% |
| 2020-12-31 | €192.35 Million | +71.17% |
| 2019-12-31 | €112.38 Million | +85.90% |
| 2018-12-31 | €60.45 Million | -29.21% |
| 2017-12-31 | €85.39 Million | +104.73% |
| 2016-12-31 | €41.71 Million | -- |